QUÉBEC CITY, Jan. 14, 2014
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced the closing of its previously
announced public offering of 11.0 million units (the "Offering")
generating net proceeds of approximately US$12.2 million, with each unit consisting of one
common share and 0.8 of a warrant to purchase one common share, at
a purchase price of US$1.20 per unit.
Each warrant is exercisable for a period of five years at an
exercise price of US$1.25 per share.
Canaccord Genuity Inc. acted as the sole book-running manager, and
Maxim Group LLC, H. C. Wainwright
& Co., LLC and MLV & Co LLC acted as co-managers for the
Offering.
The Company intends to use the net proceeds from the Offering to
continue to fund its ongoing drug development activities, primarily
for the advancement of its zoptarelin doxorubicin program, secondly
for its macimorelin acetate program, including the
preparation of its commercial launch, for the potential addition of
commercialized products to its pipeline as well as for future
negative cash flow, general corporate purposes and working
capital.
This press release does not and shall not constitute an
offer to sell or the solicitation of an offer to buy any of the
Company's securities, nor shall there be any sale of the Company's
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing novel treatments in oncology and
endocrinology. The Company's pipeline encompasses compounds from
drug discovery to regulatory approval. For more information, visit
www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbour provisions of the U.S. Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the risk that safety and efficacy data from any of our
Phase 3 trials may not coincide with the data analyses from
previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to efficiently commercialize one or more of
its products or product candidates, the ability of the Company to
take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult
the Company's quarterly and annual filings with the Canadian and
U.S. securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The
Company does not undertake to update these forward-looking
statements. We disclaim any obligation to update any such factors
or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a
governmental authority or by applicable law.
SOURCE Aeterna Zentaris Inc.